Halogen bonds form the basis for selective P-TEFb inhibition by DRB

Area of Science:

• Molecular biology
• Structural biology
• Drug discovery

Background:

• Cyclin-dependent kinase 9 (Cdk9) is essential for RNA polymerase II transcription.
• Cdk9 inhibition is a key mechanism for anticancer drugs.
• Developing selective Cdk9 inhibitors is a therapeutic goal.

Purpose of the Study:

• To elucidate the molecular basis of DRB selectivity for Cdk9 over Cdk2.
• To provide insights for designing novel, selective Cdk9 inhibitors.

Main Methods:

• X-ray crystallography to determine the structures of Cdk9-DRB and Cdk2-DRB complexes.
• Biochemical assays (kinetic and thermodynamic) to validate structural findings.

Main Results:

• Crystal structures reveal specific halogen bonds between DRB chlorine atoms and the Cdk9 hinge region.
• These interactions explain DRB's selectivity for Cdk9.
• C-terminal residues of Cdk9 contribute to DRB binding affinity.

Conclusions:

• Halogen bonds are key to DRB's selective inhibition of Cdk9.
• This understanding can guide the rational design of Cdk9-specific inhibitors.
• Exploiting halogen interactions offers a strategy for targeted cancer therapy.